Velcade "Impressive" Efficacy Offsets Concerns Over Response As Endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
"Impressive" and "better than expected" efficacy results with Millennium’s multiple myeloma agent Velcade were enough to outweigh FDA’s concerns about the use of response rate as a surrogate endpoint, NDA review documents indicate.